AU2019384626A1 - Glutarimide derivative for overcoming resistance to steriods - Google Patents

Glutarimide derivative for overcoming resistance to steriods Download PDF

Info

Publication number
AU2019384626A1
AU2019384626A1 AU2019384626A AU2019384626A AU2019384626A1 AU 2019384626 A1 AU2019384626 A1 AU 2019384626A1 AU 2019384626 A AU2019384626 A AU 2019384626A AU 2019384626 A AU2019384626 A AU 2019384626A AU 2019384626 A1 AU2019384626 A1 AU 2019384626A1
Authority
AU
Australia
Prior art keywords
compound
steroid
pharmaceutical composition
therapy
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019384626A
Other languages
English (en)
Inventor
Vladimir Evgenievich Nebolsin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
"chemimmune Therapeutics" LLC
Original Assignee
Chemimmune Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemimmune Therapeutics LLC filed Critical Chemimmune Therapeutics LLC
Publication of AU2019384626A1 publication Critical patent/AU2019384626A1/en
Priority to AU2022256212A priority Critical patent/AU2022256212B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019384626A 2018-11-23 2019-11-22 Glutarimide derivative for overcoming resistance to steriods Abandoned AU2019384626A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022256212A AU2022256212B2 (en) 2018-11-23 2022-10-21 Glutarimide derivative for overcoming resistance to steriods

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2018141291A RU2712281C1 (ru) 2018-11-23 2018-11-23 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
RU2018141291 2018-11-23
PCT/RU2019/050225 WO2020106191A1 (ru) 2018-11-23 2019-11-22 Производное глутаримида для преодоления резистентности к стероидам

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022256212A Division AU2022256212B2 (en) 2018-11-23 2022-10-21 Glutarimide derivative for overcoming resistance to steriods

Publications (1)

Publication Number Publication Date
AU2019384626A1 true AU2019384626A1 (en) 2021-07-15

Family

ID=69624712

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019384626A Abandoned AU2019384626A1 (en) 2018-11-23 2019-11-22 Glutarimide derivative for overcoming resistance to steriods
AU2022256212A Active AU2022256212B2 (en) 2018-11-23 2022-10-21 Glutarimide derivative for overcoming resistance to steriods

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022256212A Active AU2022256212B2 (en) 2018-11-23 2022-10-21 Glutarimide derivative for overcoming resistance to steriods

Country Status (19)

Country Link
US (1) US20220362230A1 (https=)
EP (2) EP4218758A3 (https=)
JP (2) JP2022508167A (https=)
KR (2) KR20220162821A (https=)
CN (2) CN114652721A (https=)
AU (2) AU2019384626A1 (https=)
BR (1) BR112021009801A2 (https=)
CA (1) CA3120882A1 (https=)
CL (2) CL2021001316A1 (https=)
EA (1) EA201992646A1 (https=)
GE (4) GEAP202215712A (https=)
IL (2) IL297533A (https=)
MD (2) MD4844C1 (https=)
MX (2) MX2021006032A (https=)
MY (1) MY209416A (https=)
PH (1) PH12021551152A1 (https=)
RU (1) RU2712281C1 (https=)
WO (1) WO2020106191A1 (https=)
ZA (2) ZA202104247B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями
WO2023191666A1 (ru) * 2022-03-29 2023-10-05 Общество С Ограниченной Ответственностью "Валента-Интеллект" Кристаллическая форма 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона и ее применение

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9111874U1 (de) * 1991-09-23 1991-11-21 Haag, Richard, 7181 Satteldorf Halterung zur Aufnahme und Befestigung von Akkus am Heckbrett in Booten
EP0625045A4 (en) * 1992-02-07 1995-01-18 Albert M Kligman METHOD FOR TREATING FLAMMABLE DERMATOS.
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20090087425A1 (en) 2007-08-10 2009-04-02 Topigen Pharmaceuticals Inc. Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease
RU2404792C1 (ru) * 2009-05-20 2010-11-27 Общество с ограниченной ответственностью Научно-производственное предприятие "БИОНОКС" Средство для преодоления стероидной резистентности
US20140112913A1 (en) * 2011-02-10 2014-04-24 Genqual Corporation Methods of prognosing and administering treatment for inflammatory disorders
JP2014511181A (ja) 2011-02-24 2014-05-15 ファーマキシス リミテッド キメラ骨格および２−アミノ−２’−デオキシアデノシンを有するオリゴヌクレオチド阻害剤
CN110128406B (zh) * 2013-04-12 2021-08-27 制药有限责任公司 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法
RU2552929C1 (ru) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
GEP20227402B (en) * 2017-09-07 2022-08-10 Valenta Intellekt Ltd Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines

Also Published As

Publication number Publication date
MD20210050A2 (ro) 2021-12-31
WO2020106191A1 (ru) 2020-05-28
EP4218758A2 (en) 2023-08-02
JP2022508167A (ja) 2022-01-19
JP7518997B2 (ja) 2024-07-19
MD4851B1 (ro) 2023-04-30
PH12021551152A1 (en) 2021-10-25
GEP20237467B (en) 2023-02-10
MD4844C1 (ro) 2023-09-30
MD4844B1 (ro) 2023-02-28
CN114652721A (zh) 2022-06-24
IL283317A (en) 2021-07-29
ZA202210444B (en) 2023-01-25
MX2022013503A (es) 2022-11-16
EP4218758A3 (en) 2023-08-23
JP2023015333A (ja) 2023-01-31
EP3884945A1 (en) 2021-09-29
CA3120882A1 (en) 2020-05-28
IL297533A (en) 2022-12-01
AU2022256212A1 (en) 2022-12-08
MD4851C1 (ro) 2023-11-30
KR20220162821A (ko) 2022-12-08
CL2022000683A1 (es) 2022-10-28
RU2712281C1 (ru) 2020-01-28
CN113164464A (zh) 2021-07-23
CL2021001316A1 (es) 2021-10-29
GEP20247643B (en) 2024-07-10
EA201992646A1 (ru) 2020-05-31
MX2021006032A (es) 2021-07-06
KR20210095652A (ko) 2021-08-02
MY209416A (en) 2025-07-08
US20220362230A1 (en) 2022-11-17
AU2022256212B2 (en) 2024-08-15
GEAP202215712A (en) 2022-10-10
GEAP202415619A (en) 2024-03-11
ZA202104247B (en) 2023-03-29
BR112021009801A2 (pt) 2022-03-03
EP3884945A4 (en) 2022-11-23
MD20210032A2 (ro) 2021-09-30

Similar Documents

Publication Publication Date Title
EP2969010B1 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
US10806735B2 (en) Use of neutrophil elastase inhibitors in liver disease
US6930093B2 (en) Use of ribofuranose derivatives against inflammatory bowel diseases
AU2022256212B2 (en) Glutarimide derivative for overcoming resistance to steriods
JP2005508346A (ja) 免疫炎症疾患の治療のための組合せ
EP3256124B1 (en) Composition comprising cenicriviroc and fumaric acid for use in the treatment of acute liver injury or peritonitis
CN109432431B (zh) 一种含有sumo抑制剂的组合物及应用
US11439631B2 (en) Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
JP2016153374A (ja) 炎症性疾患を治療又は予防するための医薬組成物
OA20849A (en) Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling.
OA20833A (en) Use of Glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling.
EA046267B1 (ru) Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
JP2021075469A (ja) 植物由来アルカロイドを含有する医薬組成物
EA043839B1 (ru) Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
HK40074427A (en) USE OF GLUTARIMIDE DERIVATIVES FOR OVERCOMING STEROID RESISTANCE AND TREATING DISEASES ASSOCIATED WITH ABERRANT INTERFERON γ SIGNALING
CN111343983A (zh) 使用ccr3抑制剂治疗瘙痒、干燥症和相关疾病的方法和组合物
HK40059361A (en) Glutarimide derivative for overcoming resistance to steriods
EP1565215A2 (en) Use of the corticoliberin-urocortin system in the treatment of inflammatory diseases
WO2020135872A1 (zh) 免疫抑制药物组合物及其应用
US20240226057A1 (en) New use of monensin
EP4703368A1 (en) Isolithocholic acid derivatives and use thereof
CN110891580A (zh) 使用三氧化二砷治疗多发性硬化症的方法
JP2001512446A (ja) メラニンによるサイトカインの調整
CN113197898A (zh) 卡博替尼在制备防治nlrp3炎症小体相关疾病的药物中的应用
Aumais et al. Rectal tissue, plasma, and urine concentrations of mesalamine (5-ASA) after single and multiple administrations of suppositories to ulcerative proctitis (UP) patients

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application